1. Home
  2. CDMO vs CCAP Comparison

CDMO vs CCAP Comparison

Compare CDMO & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDMO
  • CCAP
  • Stock Information
  • Founded
  • CDMO 1981
  • CCAP 2015
  • Country
  • CDMO United States
  • CCAP United States
  • Employees
  • CDMO N/A
  • CCAP N/A
  • Industry
  • CDMO Biotechnology: Pharmaceutical Preparations
  • CCAP Finance: Consumer Services
  • Sector
  • CDMO Health Care
  • CCAP Finance
  • Exchange
  • CDMO Nasdaq
  • CCAP Nasdaq
  • Market Cap
  • CDMO 793.8M
  • CCAP 732.0M
  • IPO Year
  • CDMO N/A
  • CCAP N/A
  • Fundamental
  • Price
  • CDMO $12.39
  • CCAP $19.34
  • Analyst Decision
  • CDMO Hold
  • CCAP Buy
  • Analyst Count
  • CDMO 3
  • CCAP 6
  • Target Price
  • CDMO $12.25
  • CCAP $19.17
  • AVG Volume (30 Days)
  • CDMO 1.3M
  • CCAP 103.3K
  • Earning Date
  • CDMO 12-10-2024
  • CCAP 02-19-2025
  • Dividend Yield
  • CDMO N/A
  • CCAP 10.55%
  • EPS Growth
  • CDMO N/A
  • CCAP 57.74
  • EPS
  • CDMO N/A
  • CCAP 2.55
  • Revenue
  • CDMO $150,445,000.00
  • CCAP $200,903,000.00
  • Revenue This Year
  • CDMO $19.05
  • CCAP $9.80
  • Revenue Next Year
  • CDMO $20.88
  • CCAP N/A
  • P/E Ratio
  • CDMO N/A
  • CCAP $7.58
  • Revenue Growth
  • CDMO 6.75
  • CCAP 19.05
  • 52 Week Low
  • CDMO $5.90
  • CCAP $15.91
  • 52 Week High
  • CDMO $12.48
  • CCAP $20.03
  • Technical
  • Relative Strength Index (RSI)
  • CDMO 61.55
  • CCAP 53.05
  • Support Level
  • CDMO $12.37
  • CCAP $18.30
  • Resistance Level
  • CDMO $12.45
  • CCAP $19.41
  • Average True Range (ATR)
  • CDMO 0.04
  • CCAP 0.32
  • MACD
  • CDMO -0.02
  • CCAP -0.00
  • Stochastic Oscillator
  • CDMO 71.43
  • CCAP 65.00

About CDMO Avid Bioservices Inc.

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

About CCAP Crescent Capital BDC Inc. Common stock

Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.

Share on Social Networks: